Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 340

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling

Jansen, Maurice P.H.M., Foekens, John A., van Staveren, Iris L., Dirkzwager-Kiel, Maaike M., Ritstier, Kirsten, Look, Maxime P., Meijer-van Gelder, Marion E., Sieuwerts, Anieta M., Portengen, Henk, Dorssers, Lambert C.J., Klijn, Jan G.M., Berns, Els M.J.J.·2005·Journal of Clinical Oncology

Abstract

Purpose: To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling. Patients and Methods: The study was performed on 112 estrogen receptor–positive primary breast carcinomas from patients with advanced disease and clearly defined types of response (ie, 52 patients with objective response v 60 patients with progressive disease) from start of first-line treatment with tamoxifen. Main clinical end points are the effects of therapy on tumor size and time until tumor progression (progression-free survival [PFS]). RNA isolated from tumor samples was amplified and hybridized to 18,000 human cDNA microarrays. Results: Using a training set of 46 breast tumors, 81 genes were found to be differentially expressed (P ≤ .05) between tamoxifen-responsive and -resistant tumors. These genes were involved in estrogen action, apoptosis, extracellular matrix formation, and immune response. From the 81 genes, a predictive signature of 44 genes was extracted and validated on an independent set of 66 tumors. This 44-gene signature is significantly superior (odds ratio, 3.16; 95% CI, 1.10 to 9.11; P = .03) to traditional predictive factors in univariate analysis and also significantly related with a longer PFS in univariate (hazard ratio, 0.54; 95% CI, 0.31 to 0.94; P = .03) as well as in multivariate analyses (P = .03). Conclusion: Our data show that gene expression profiling can be used to discriminate between breast cancer patients with progressive disease and objective response to tamoxifen. Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.05.145

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 340

Metadata

Authors
Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., Meijer-van Gelder, M. E., Sieuwerts, A. M., Portengen, H., Dorssers, L. C. J., Klijn, J. G. M., & Berns, E. M. J. J.
Venue
Journal of Clinical Oncology
Published
2005-02-01
Volume
23
Issue
4
Pages
732-740
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2143185770
Cited by
340
References
33
FWCI
15.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. https://app.cochat.ai/papers/10.1200/jco.2005.05.145
The paper
Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., Meijer-van Gelder, M. E., Sieuwerts, A. M., Portengen, H., Dorssers, L. C. J., Klijn, J. G. M., & Berns, E. M. J. J. (2005). Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.05.145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.